Grasim Q1 -Standalone net profit at Rs 320.9 crore versus Rs 134.5 crore (YoY) -Standalone total income up 24.6 percent at Rs 2,426.5 crore versus Rs 1,947 crore (YoY) -Standalone EBITDA up 86.5 percent at Rs 538.4 crore versus Rs 288.8 crore (YoY) -Standalone EBITDA margin at 22.2 percent versus 14.8 percent (YoY)
Aditya Birla Nuvo Q1 -Consolidated net profit down 56.8 percent at Rs 305.1 crore versus Rs 706.2 crore (YoY) -Total income up 0.2 percent at Rs 3,194 crore versus Rs 3,188 crore (YoY) -EBITDA down 30.7 percent at Rs 848.6 crore versus Rs 649.2 crore (YoY) -EBITDA margin at 26.6 percent versus 20.4 percent (YoY)
Prime Focus Q1 -Net profit of Rs 106.2 crore versus loss of Rs 213.8 crore (YoY) -Total income up 1.5 percent at Rs 526.2 crore versus Rs 518.2 crore (YoY) -EBITDA up 17.85 at Rs 101.4 crore versus Rs 86.1 crore (YoY) -EBITDA margin at 19.3 percent versus 16.6 percent (YoY)
Sharon Bio Q1 -Net loss at Rs 179.4 crore versus Rs 82.4 crore (YoY) -Total income down 73.3 percent at Rs 37.8 crore versus Rs 142 crore (YoY)
Alkem Labs -USFDA gives nod to company's bioequivalence facility at Taloja, Maharashtra -USFDA inspected Taloja unit from August 1-10; no 483s issued
Epic Research aware of traders by serving daily live stock market news. Follow services of this firm and make your investment successful.
ReplyDelete